Skip to main content
Premium Trial:

Request an Annual Quote

Emerald BioStructures, UCB Expand Drug Discovery Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB today said that they have a achieved a second milestone in their ongoing collaboration and have expanded the alliance.

Bainbridge Island, Wash.-based Emerald said that it and UCB researchers have solved high-resolution X-ray crystallographic structures of multiple targets and have identified a unique lead series of small molecules. The firm said that it achieved that milestone within two years, since the firms initiated their collaboration in January 2009.

Emerald also said that the firms have decided to expand the agreement, though it provided few details. The expansion will result in undisclosed research fees, a milestone payment, and royalties. Emerald said that the financial terms would support multiple full-time researcher equivalents at the firm.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.